Clay Siegall leads Seattle Genetics in unveiling 12 new cancer treatment drugs

Seattle Genetics is a company that engages in commercialization and development of antibody drugs that fight cancer. Their main product sold across commercial stores has the label Adcetris. The product has been approved by the Health Association and the U.S. Food and Drug Association in both Canada and the U.S. Adcetris is a drug that focuses on producing antibodies that conjugate cancer cells hence destroying them. The company was found by H. Perry Fell and Clay B. Siegall on July 1997. The company is today headquartered at Bothell, WA.

Dr. Siegall has played the lead role in Seattle genetics success. He graduated with a Ph.D. in Genetics received from George Washington University. He holds a Bachelor of Science in Zoology from Maryland University. Before becoming the CEO of the Seattle Genetics company, he worked at several research institutes. He dedicated a large part of his life between 1988 and 1997 to cancer and research institutions. Seattle Genetics has grown to become a popular biotech company. It focuses on commercialization, development and innovation of cancer patients.

Seattle Genetics today has a plan to expand the use of its cancer drug and increase its shelf with new drugs. The company wants to increase the number of employees so as to achieve its vision quickly and efficiently. According to the company CEO Dr. Clay Siegall, the company has tried its first drug in about 70 different occasions used to treat cancer cells. Results from the drug have been amazing, the drug has been used to fight lymphomas and managed to give the company revenues worth $226 million in 2015. The company has since partnered with pharmaceuticals that aid in selling drugs in Canada and the US. Its partnership with Takeda Pharmaceuticals has seen Seattle increase its market for drug sales.

Dr. Clay Siegall is behind the massive success of the company. Through his efforts, the company has managed to secure more than $675 million in fundraising. Siegall’s main drive is to discover the cure for the disease that claims lives of thousands of people every year. His passion has seen him help the company in terms of private and public fundraising.

Leave a Reply